Lisanti Capital Growth LLC Buys 79,365 Shares of AtriCure, Inc. $ATRC

Lisanti Capital Growth LLC acquired a new position in shares of AtriCure, Inc. (NASDAQ:ATRC) during the 3rd quarter, HoldingsChannel reports. The firm acquired 79,365 shares of the medical device company’s stock, valued at approximately $4,460,000.

Several other hedge funds and other institutional investors also recently modified their holdings of ATRC. Harbor Investment Advisory LLC bought a new position in AtriCure in the 2nd quarter worth about $40,000. Allworth Financial LP acquired a new stake in shares of AtriCure in the second quarter valued at $43,000. Integrated Wealth Concepts LLC acquired a new stake in AtriCure in the 2nd quarter valued at about $46,000. Fifth Third Bancorp bought a new stake in AtriCure during the first quarter worth approximately $51,000. Finally, Global Retirement Partners LLC acquired a new position in shares of AtriCure in the 2nd quarter worth $52,000. Institutional investors and hedge funds own 99.11% of the company’s stock.

Insider Activity at AtriCure

In related news, Director Regina Groves sold 5,313 shares of the firm’s stock in a transaction on Friday, September 11th. The stock was sold at an average price of $54.22, for a total transaction of $288,070.86. Following the sale, the director owned 34,546 shares of the company’s stock, valued at approximately $1,873,084.12. This trade represents a 13.33% decrease in their position. The sale was disclosed in a filing with the SEC, which can be accessed through this link. Also, insider Salvatore Privitera sold 8,404 shares of AtriCure stock in a transaction dated Wednesday, November 4th. The shares were sold at an average price of $65.00, for a total value of $546,260.00. Following the transaction, the insider owned 134,341 shares in the company, valued at $8,732,165. This trade represents a 5.89% decrease in their position. The disclosure for this sale is available in the SEC filing. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Insiders sold a total of 39,026 shares of company stock worth $2,172,263 in the last quarter. Corporate insiders own 4.00% of the company’s stock.

Wall Street Analysts Forecast Growth

Several brokerages recently commented on ATRC. Raymond James Financial set a $52.00 price target on shares of AtriCure in a research report on Tuesday, July 21st. UBS Group cut shares of AtriCure from a “buy” rating to a “sell” rating in a research note on Wednesday, October 21st. JPMorgan Chase & Co. upped their price target on AtriCure from $36.00 to $62.00 and gave the stock a “neutral” rating in a research note on Wednesday, November 4th. Weiss Ratings raised shares of AtriCure from a “hold (c-)” rating to a “hold (c)” rating in a research report on Thursday, October 8th. Finally, Canaccord Genuity Group boosted their price target on AtriCure from $55.00 to $67.00 and gave the company a “buy” rating in a research note on Wednesday, November 4th. One research analyst has rated the stock with a Strong Buy rating, six have issued a Buy rating, four have given a Hold rating and one has issued a Sell rating to the company’s stock. According to MarketBeat, AtriCure currently has an average rating of “Moderate Buy” and a consensus target price of $61.80.

AtriCure Trading Up 2.3%

ATRC stock opened at $57.53 on Thursday. AtriCure, Inc. has a twelve month low of $25.36 and a twelve month high of $66.02. The company has a market cap of $2.93 billion, a P/E ratio of 191.77 and a beta of 1.23. The company has a quick ratio of 3.29, a current ratio of 4.33 and a debt-to-equity ratio of 0.17. The business has a fifty day moving average of $57.32 and a 200-day moving average of $39.00.

AtriCure (NASDAQ:ATRC) last issued its earnings results on Tuesday, November 3rd. The medical device company reported $0.17 EPS for the quarter, beating the consensus estimate of ($0.06) by $0.23. The company had revenue of $154.45 million during the quarter, compared to analysts’ expectations of $151.05 million. AtriCure had a net margin of 2.52% and a return on equity of 4.01%. As a group, equities research analysts expect that AtriCure, Inc. will post 0.44 EPS for the current year.

AtriCure Profile

AtriCure, Inc. is a medical technology company that develops and sells products for the treatment of atrial fibrillation and other conditions addressed through cardiac surgery. Its technologies are used by surgeons and other medical professionals in hospital settings. The company’s products include surgical ablation systems designed to treat irregular heart rhythms and devices for managing the left atrial appendage, a small pouch in the heart associated with stroke risk in some patients with atrial fibrillation.